Anzeige
Mehr »
Sonntag, 13.07.2025 - Börsentäglich über 12.000 News
Starkes Kaufsignal: MEGA-Ausbruch bei Silber steht kurz bevor!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EKSZ | ISIN: CA68237C1059 | Ticker-Symbol: W1H
Tradegate
11.07.25 | 21:56
1,240 Euro
+2,48 % +0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCO-INNOVATIONS LIMITED Chart 1 Jahr
5-Tage-Chart
ONCO-INNOVATIONS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
1,2001,26012.07.
1,1601,25011.07.
ACCESS Newswire
393 Leser
Artikel bewerten:
(2)

Onco-Innovations Limited: Onco-Innovations' CEO to Host Special Investors' Conference Call on Wednesday, July 2, 2025

VANCOUVER, BC / ACCESS Newswire / June 25, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H), (WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Mr. Thomas O'Shaughnessy, Onco-Innovations' CEO, will host a special investors' conference call, on Wednesday, July 2, 2025 at 2:00 p.m. PST/5:00 p.m. ET/11:00 p.m. CET.

Participants are invited to send in advance questions for Mr. O'Shaughnessy to address during the conference, by submitting to investors@oncoinnovations.com.

Please call in 10 minutes before the conference call starts and stay on the line.

CALL INTO THE LIVE EVENT:

Conference Link "Dial Me":
https://link.meetingpanel.com/?id=onco-innovations-limited-special-investors-announcement

(Conference Link's 'Dial Me' feature lets participants join the call instantly-no dial-in or hold time. By entering their name, company, email, and phone number, the platform will call them directly to connect.)

or

Participant Toll-Free Number: 888-304-1803
International / Direct Dial: 848-488-9277
Germany: +49 69 5899 64215

Conference ID: ONCO

The Company will issue a press release after the conclusion of the conference call.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/onco-innovations-ceo-to-host-special-investors-conference-call-on-wed-1043216

© 2025 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.